FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Forschung/Papier
Zurück zur Forschungsbibliothek
PubMedHuman TrialMenschliche Versuchspersonen

Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.

Rodriguez Patricia J, Zhang Vincent, Gratzl Samuel, Do Duy, Goodwin Cartwright Brianna, Baker Charlotte, Gluckman Ty J, Stucky Nicholas, Emanuel Ezekiel J
JAMA network open2025DOI: 10.1001/jamanetworkopen.2024.57349
GLP-1 receptor agonistsliraglutidesemaglutidetirzepatide

Qualitätsbewertung

6/10

Zitate

0

Themen

Mensch

Peptide Contacts Analyse

Study Design

Human trial data is the most directly translatable evidence for therapeutic applications. The physiological responses observed here reflect real human biology, not extrapolations from animal models.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide in meaningful ways. The human-subjects design makes these results particularly relevant for clinical translation.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Decent human data on GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide. Not the final word, but a meaningful data point that adds to the weight of evidence.

Wichtige Erkenntnisse

The study found that patients without type 2 diabetes had higher discontinuation rates of GLP-1 receptor agonists compared to those with type 2 diabetes. Weight loss and higher income were associated with lower discontinuation rates, while gastrointestinal adverse events increased the risk of discontinuation.

Beschränkungen

The retrospective nature of the study limits causal inference, and the reliance on electronic health records may introduce selection bias or missing data issues.

Wie man diese Forschung interpretieren soll

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Examine the primary endpoint — did the study measure what actually matters clinically, or a proxy marker?

4

Statistical significance (p < 0.05) does not always mean clinical significance. Look at the actual effect size.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts Analyse

Exploring the Adherence Challenges and Influencing Factors of GLP-1 Receptor Agonists Among Patients With Overweight or Obesity

GLP-1 receptor agonistsliraglutidesemaglutidetirzepatide

Adherence Challenges to GLP-1 Receptor Agonists: Insights from a Large-Scale Retrospective Study

Published: May 16, 2026 | Source: JAMA network open (2025) | Category: GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide

Overview

A recent study published in the JAMA Network Open has shed light on the adherence challenges faced by patients using glucagon-like peptide-1 (GLP-1) receptor agonists for weight management. The research reveals that individuals without type 2 diabetes are more likely to discontinue their GLP-1 treatment compared to those with the condition, highlighting significant differences in patient adherence patterns.

Study Background

GLP-1 receptor agonists have become a cornerstone of obesity and diabetes management due to their effectiveness in weight loss and glycemic control. However, ensuring long-term adherence remains a critical challenge. Previous studies have noted varying levels of discontinuation rates but lacked detailed insights into the factors influencing these decisions among patients with overweight or obesity.

What the Research Found

The study analyzed data from 125,474 adults who started using GLP-1 receptor agonists (liraglutide, semaglutide, or tirzepatide) between January 1, 2018, and December 31, 2023. Among these patients, 61% had type 2 diabetes. The research found that one-year discontinuation rates were significantly higher for those without type 2 diabetes (64.8%) compared to those with the condition (46.5%). Furthermore, weight loss was associated with lower risks of discontinuing treatment: a 1% reduction in weight from baseline correlated with a 3.1% and 3.3% decrease in discontinuation risk for patients with and without type 2 diabetes, respectively.

What This Means for Peptide Users

The findings suggest that adherence to GLP-1 receptor agonists is influenced by the presence of type 2 diabetes and weight loss outcomes. Patients without type 2 diabetes may face additional challenges in maintaining long-term treatment adherence due to factors such as perceived necessity or side effects like gastrointestinal issues, which can be mitigated through better patient education and support.

Limitations and Caveats

The retrospective nature of the study limits its ability to establish causality between variables. Additionally, reliance on electronic health records introduces potential biases related to data completeness and accuracy. These limitations underscore the need for further research using prospective designs to confirm these findings and explore additional influencing factors such as patient education levels and socioeconomic status.

How This Compares to Previous Research

Previous studies have also noted higher discontinuation rates among patients with overweight or obesity, but this study provides a more nuanced understanding by stratifying results based on the presence of type 2 diabetes. The association between weight loss and adherence aligns with earlier research that emphasized the importance of treatment efficacy in sustaining patient engagement.

Our Analysis

PeptideVault views this study as an important contribution to our understanding of GLP-1 receptor agonist adherence, particularly among patients without type 2 diabetes. While it highlights critical areas for improvement, such as addressing gastrointestinal side effects and enhancing patient education, the retrospective design limits definitive conclusions about causality.

Key Takeaways

  • Higher Discontinuation Rates: Patients without type 2 diabetes have higher discontinuation rates compared to those with the condition.
  • Weight Loss Impact: Weight loss is associated with improved adherence to GLP-1 receptor agonists.
  • Gastrointestinal Side Effects: These are significant factors in treatment discontinuation, underscoring the need for better management strategies.

Original Source

Citation: Rodriguez Patricia J, Zhang Vincent, Gratzl Samuel et al. (2025). Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.. JAMA network open. DOI: 10.1001/jamanetworkopen.2024.57349

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Bearbeitungsnotiz

Diese Analyse wurde vom Peptide Contacts-Forscherteam verfasst, um komplexe Erkenntnisse für die Peptidcommunity zugänglich zu machen. Wir ermutigen Leser, das Quellpapier für vollständige Methoden und Daten zu überprüfen. Für mehr zum GLP-1 receptor agonists, entdecken Sie unsere Forschungshinweise.

Zitation

Rodriguez Patricia J, Zhang Vincent, Gratzl Samuel et al.. (2025). Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.. JAMA network open. https://doi.org/10.1001/jamanetworkopen.2024.57349

Ganzer Text auf PubMed ansehen

Verwandte Papiere

Weiter entdecken

Dieses Inhalte basiert auf peer-bewerteter Forschung zur Bildungszwecke. Sie bildet keine medizinische Beratung aus. Stets beraten Sie sich mit einer qualifizierten Gesundheitsversorgerin, bevor Sie irgendeine Peptidbasierte Therapie verwenden.